Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lycored Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, so the pending work is divided between separate examination settings.
FIEBIG, RUSSELL G is the busiest examiner, with 1 pending matter. Practitioners should preserve consistency in the biotechnology and pharmaceutical claim strategy while tailoring each response.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767902 | COMPOSITIONS AND METHODS FOR INHIBITING COLLAGEN LOSS | FAY, ZOHREH ALEMZADEH | 19d overdue |
| 18701781 | PHYTOENE-CONTAINING OLEORESIN AND COMPOSITION | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701781 | PHYTOENE-CONTAINING OLEORESIN AND COMPOSITION | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701781 | PHYTOENE-CONTAINING OLEORESIN AND COMPOSITION | FIEBIG, RUSSELL G | 1655 | §101§103 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 17767902 | COMPOSITIONS AND METHODS FOR INHIBITING COLLAGEN LOSS | FAY, ZOHREH ALEMZADEH | 1617 | §101§103 | Final Rejection | 19d overdue | Pending | Apr 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLycored Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Russell G Fiebig has the most, with 1 of Lycored Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
